+54 (230) 438-8888

Profesionales

Gabín María Noel

Oftalmología - Médica de staff / Oftalmología Infantil - Médica de staff

Formación

Médica

Especialización

  • Residencia completa hospital Medalla Milagrosa.
  • Fellowship Retina HUA.
  • Especialista Oftalmología USAL.

Docencia

  • Ayudante de cátedra Fisiología (endocrinología-neurolofisiología) Escuela de medicina Hospital Italiano.

Últimas Participaciones en Congresos o Cursos

SANTEN Study 32-007 “A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye” SANTEN INCORPORATED GENENTECH Study FVF 4168g “A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION–CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS” GENENTECH ABBOT Study M10-880 “Phase III study, A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis” VISUAL I. AbbVIE (Abbott) Study M10-877 “Phase III study, A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis” - VISUAL II. AbbVIE (Abbott) Study M10-327 “phase iii study, A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Noninfectious Intermediate-, Posterior-, or Pan-uveitis” - VISUAL III. AbbVIE (Abbott) OPHTHOTECH STUDY OPH1003 ”FOVISTA”. A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTATM (ANTI PDGF-B PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH LUCENTIS® COMPARED TO LUCENTIS® MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. opHtHOTECH ALCON (AZARGA) Study RDG 11-198 “phase iii study, Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America” Alcon
Solicitar turno